Study of Omega-3 Replacement with Krill Oil in Treatment of Systemic Lupus Erythematosus

Clinical Trial Title:
Study to assess clinical benefit of omega-3 replacement with krill oil in disease management of SLE.

Clinical Trial Protocol ID: 18022805
Clinical Trial Investigator Name: Meenakshi Jolly, MD

Clinical Trial Protocol Description:
The study is a 24 week randomized, double-blind controlled multicenter study followed by an open label extension treatment for another 24 weeks. The purpose of this study is to determine whether the correction of the omega-3 deficiency may reduce disease activity in SLE patients.

Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:

Have a clinical diagnosis of systemic lupus erythematosus (SLE).
You will be excluded from the study if any of the following criteria apply to you:

Have rapidly progressive neurologic or renal disease.
Are using an omega-3 prescription drug (e.g. Lovaza®, Vascepa®, etc.) or as medical food (e.g. Vascazen®, Vayarin, Onemia™ etc.).

Are currently using or have recently used (within 3 months of screening) any OTC fish or krill oil dietary supplement, or any long-chain omega-3 fatty acid dietary supplement (e.g., MegaRed).

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: Arthritis and Other Rheumatic Diseases
Contact Phone: (312) 563-2955
Contact Name: Joshlean Fair

Download a flyer here